Background {#Sec1}
==========

Low molecular weight heparins (LMWH) are among the preferred anticoagulant for preventing and treating venous thrombosis \[[@CR1]\]. A meta-analysis of randomized controlled trials showed similar efficacy between LMWH and unfractionated heparin (UFH) for acute deep venous thrombosis prevention, and no bleeding risk difference \[[@CR2]\] with a reduced mortality rate in favor of LMWH. \[[@CR2]\] LMWH are replacing UFH as the first line treatment for pulmonary embolism and unstable angina, a choice mainly due to their predictable effect and convenient use \[[@CR3]\].

Despite the fact that the European Best Practice Guidelines for hemodialysis recommended the use of LWMH for the extracorporeal circuit (ECC) anticoagulation, UFH remains the most frequent choice for hemodialysis treatment in North America \[[@CR4]\]. While cost may be the main argument for not using LMWH in hemodialysis, their safety remains a major concern. UFH is metabolized by both hepatic and renal pathways but LMWH are mainly cleared through the kidneys leading to a potential bioaccumulation and an increased risk of hemorrhage \[[@CR5]\]. A meta-analysis conducted by Lim et al. evaluated the safety and efficacy of LMWH in hemodialysis, finding no difference between LMWH and UFH for both bleeding and thrombosis of the ECC. While the sample was large enough to evaluate efficacy (thrombosis), limited data was available to evaluate the risk of bleeding, leading to large confidence intervals (CI), and therefore limited conclusions \[[@CR6]\].

UFH is known to modify the lipid profile, to induce osteoporosis, and to carry a risk of heparin-induced thrombocytopenia (HIT). However, the impact of LMWH on these outcomes in hemodialysis remains unclear \[[@CR7]\].

The aim of this systematic review was to evaluate the safety of LMWH compared to UFH as an anticoagulant of the ECC among patients undergoing chronic hemodialysis. The primary outcomes were the risk of minor and major bleedings, cardiovascular events and osteoporotic fractures. Secondary outcomes were changes in lipid profile, osteoporosis and HIT.

Methods {#Sec2}
=======

Two independent reviewers (HHL and ER) conducted the study selection, validity assessment and data extraction with disagreement solved by a third reviewer (JPL).

Performed searches {#Sec3}
------------------

Databases were screened to retrieve prospective experimental studies comparing LMWH to UFH for anticoagulation of the ECC during hemodialysis for patients with end-stage renal disease (ESRD). The search strategy was developed with a professional librarian. We searched Pubmed (from start up to January 2016), Embase (1974 to 2016 week 1), Cochrane central register of controlled trials (from start to January 2016), Trip database, the National Institute for Health and Care Excellence (NICE) and [clinicaltrials.gov/](https://clinicaltrials.gov/) with no language restriction. Performed searches were conducted by one reviewer (HHL). Reference lists of selected studies were screened manually and authors were contacted when additional data was needed (HHL and ER) Additional file [1](#MOESM1){ref-type="media"}.

Study selection {#Sec4}
---------------

Studies were selected if they fulfilled the following criteria: a) Patients were adults with ESRD undergoing chronic hemodialysis (incident or prevalent); b) LMWH was compared to UFH for anticoagulation of the ECC during hemodialysis; c) at least one of the outcomes of interest was reported (minor or major bleeding, lipid profile changes for total cholesterol, LDL-cholesterol, triglycerides, cardiovascular events, osteoporosis, osteoporotic fractures, HIT); d) the design was a prospective randomized or non-randomized cross-over or a parallel randomized study. A study was excluded if: a) it was a non-randomized parallel-design; b) it was using historical data; or c) the results were published more than once in which case only the most complete study was kept.

Quality assessment {#Sec5}
------------------

Quality of each study was assessed using the Cochrane risk of bias tool \[[@CR8]\] for randomized trials or the risk of bias in non-randomized studies (Robins-I) \[[@CR9]\]. The Cochrane risk of bias tool evaluates the methodology of the study and the potential biases in the research question context. \[[@CR8]\] There is no final score but results are reported as low, unclear or high risk of bias for different potential biases. The Robins-I uses a similar approach but is adapted to non-randomized trials.

Data extraction {#Sec6}
---------------

A common form was used to ascertain extraction of the complete study characteristics and outcomes of interest as follows: a) bleeding events classified as major and minor when specified by the authors; b) cardiovascular events; c) LDL, total-cholesterol and triglycerides levels at start and end of study for both treatment and control; d) osteoporotic fractures; e) osteoporosis diagnostic; f) bone density changes; g) OPG/RANKL biomarkers affecting bone density; and h) HIT.

Statistical analysis {#Sec7}
--------------------

The weighted kappa statistics was used to assess between reviewers agreement for study selection and quality assessment \[[@CR10]\]. We calculated relative risks (RR) and 95% confidence intervals (CI) for dichotomous clinical data. A pooled weighted mean difference (WMD) and its 95% CI were used to compare continuous outcomes. The pooled overall effect for both RR and WMD was estimated using the method described by DerSimonian and Laird \[[@CR11]\] with a random effect model for heterogeneous data. Heterogeneity was evaluated using the I^2^ statistic using a 60% significance threshold. Publication bias was assessed visually using a funnel plot and using the Egger test \[[@CR12]\]. All analyses were performed with Stata IC 11.0.

Sensitivity analyses {#Sec18}
--------------------

The pooled WMD and 95% CI were calculated based on the pre- and post-treatment measures using their standard deviations to derive the WMD's standard deviation \[[@CR8]\]. In the main analysis, the correlation factor was fixed at 0.5 based on the assumption that repeated measures would be moderately correlated. We tested the robustness of this assumption with correlation factors of 0.3 and 0.8 as sensitivity analyses.

Results {#Sec8}
=======

Identification and study selection {#Sec9}
----------------------------------

From a total of 971, we identified 17 studies \[[@CR13]--[@CR28]\] that met our pre-defined selection criteria (Fig. [1](#Fig1){ref-type="fig"}). The inter-rater agreement was excellent with a weighted kappa of 0.94 for study selection. In the meta-analysis, we included nine studies \[[@CR13]--[@CR15], [@CR22]--[@CR24], [@CR26]--[@CR28]\] that recorded bleeding episodes and 11 studies \[[@CR13], [@CR17]--[@CR21], [@CR23], [@CR24], [@CR26]--[@CR28]\] evaluating lipid changes. Of note, when a study evaluated the same outcome within two different groups of patients and different settings we considered each part of the article as an independent study for both the systematic review and the meta-analysis \[[@CR17], [@CR28]\]. All the non-English articles were translated but did not meet criteria. Five studies were with a randomized cross-over design \[[@CR16], [@CR22], [@CR24], [@CR27], [@CR29]\], nine were non-randomized cross-over \[[@CR13]--[@CR15], [@CR17], [@CR19]--[@CR21], [@CR25], [@CR28]\] and three parallel design with randomization \[[@CR18], [@CR23], [@CR26]\]. Two studies were excluded from the review since they reported the same results as studies included in the present review. Sabri et al. \[[@CR30]\] was excluded for presenting the same data and results as Al-Saran et al. \[[@CR13]\]. The same situation occurred between Schneider el al \[[@CR31]\] and Schmitt el al \[[@CR25]\].Fig. 1Study selection flow chart adapted from the PRISMA flowchart model. \*osteoporosis was not pooled with a meta-analysis (2 studies)

Characteristics of studies and patients {#Sec10}
---------------------------------------

Characteristics of studies are listed in Table [1](#Tab1){ref-type="table"}. The number of patients ranged from five to 110, and follow-up ranged between one and 60 months. Various types of LMWH were used for the experimental arm, including nadroparin, enoxaparin, tinzaparin, dalteparin, certoparin and fraxiparin. Both men and women were included with age ranging from 15 to 85 years. Exclusion criteria differed between studies but bleeding disorder was a recurrent criterion. Patient characteristics are detailed in Table [2](#Tab2){ref-type="table"}. The most common dialysis schedule was a session of four hours thrice weekly. Hemodiafiltration procedure was also used in three studies \[[@CR15], [@CR26], [@CR27]\].Table 1Characteristics of studies included in the systematic reviewStudyYearCountryFollow-upPatients enrolled (n)\
LMWH/UFH (n/n)Drop-outs (n)\
LMWH/UFH (n/n)LMWH typeLMWH mean doseUFH mean doseHD/HDFCross-over randomized design Cianciolo et al. \[[@CR16]\]2011Italy2 months400Nadroparin64 IU/kgbolus 50 IU/kg and 30 IU/kg/hHD Klejna et al. \[[@CR29]\]2014Poland6 months210Enoxaparin5280 IU ± 1120 IU4881 IU ± 1916.3 IUHD Lord et al. \[[@CR22]\]2002Canada2 months322Tinzaparin4318.2 IU ± 702.8 IU8207.9 IU ± 2530.9 IUHD Saltissi et al. \[[@CR24]\]1999Australia6 months365Enoxaparin100 IU/kgbolus 50 IU/kg and 1000 IU/hHD Stefoni et al. \[[@CR27]\]2002Italy36 months547Nadroparin64 IU/kgbolus 1500 IU and 1500 IU and 1500 IU ± 500 IU perfusionHDFCross-over non-randomized design Al-Saran et al. \[[@CR13]\]2010Saudi Arabia12 months230Tinzaparin2000--3000 IU5000 IUHD Bambauer et al. \[[@CR14]\]1990Germany12 months276Dalteparin4216 IU ± 2237 IU4958 IU ± 2561 IUHD Bramham et al. \[[@CR15]\]2008United Kingdom4 months1102Tinzaparin2500--5000 IU1000 IU ± 500--2000 IUHDF Deuber et al.\
 (part 1) \[[@CR17]\]1991Germany60 months50Non specifiedNon specified29--143 IU/kgHD Deuber et al.\
 (part 2) \[[@CR17]\]1991Germany24 months50Non specifiedNon specified29--143 IU/kgHD Kronenberg et al. \[[@CR19]\]1995Austria12 months240Certoparin44.7 IU/kg ± 21.5 IU/kg25.1 IU/kg ± 7.8 IU/kgHD Lai et al. \[[@CR20]\]2001China24 months406Nadroparin4100--6150 IU5000--7000 IUHD Leu et al. \[[@CR21]\]1998Taiwan4 months200Dalteparin2413 IU ± 954 IU2413 IU ± 954 IUHD Schmitt et al. \[[@CR25]\]1993Germany12 months220Dalteparinbolus 1500 IU and 675 IU/h ± 284 IU/hbolus 1500 IU and 1031 IU/h ± 342 IU/hHD Yang et al.\
 (part 1) \[[@CR28]\]1998Taiwan1 month100Fraxiparin10,000 ICUbolus 1800 IU ± 675 IU and 895 IU/h ± 340 IU/hHD Yang et al.\
 (part 2) \[[@CR28]\]1998Taiwan12 months102Fraxiparin192.9 ICU/kg ± 3.8 ICU/kgbolus 1800 IU ± 675 IU and 895 IU/h ± 340 IU/hHDRandomized parallel design Elisaf et al. \[[@CR18]\]1997Greece12 months76\
38/380Tinzaparin3000 IU5000--7000 IUHD Nurmohamed et al. \[[@CR23]\]1991The Netherlands6 months70\
35/3513\
8/5Nadroparin150--200 IU/kgbolus 2500 IU and 600--2200 IU/hHD Schrader et al. \[[@CR26]\]1988Germany12 months70\
35/358\
5/3Dalteparinbolus 36.8 IU/kg ± 17.3 IU/kg and 12.2 IU/kg/h ± 5.0 IU/kg/hbolus 58.3 IU/kg ± 26.3 IU/kg and 16.6 IU/kg/h ± 6.7 IU/kg/hHDF*HD* Hemodialysis, *HDF* Hemodiafiltration Table 2Participants characteristicsStudyMean age + SD (years)Age range (years)Male/Female\
(n/n)Dialysis duration and frequencyInclusion criteriaExclusion criteriaCross-over with randomization Cianciolo et al.63.3 ± 7.242--7221/194 h 3×/wkchronic HD, age 18+, stable, AVFgastrointestinal bleeding, acute cardiovascular event 3 months before, malignancy, coagulation disorders, DVT, immunosupressive therapy, acute vasculitis, liver disease, active infection, diabetes, enrolled in other clinical trial Klejna et al.68.244--8211/104--5 h 3×/wkChronic HDHIV, Hepatitis B, Hepatitis C, VTE, gastrointestinal bleeding, coagulation disorders Lord et al.66.6 ± 14.8NS17/154 h 3×/wkChronic HDPatients with catheters, with bleeding diathesis in last 3 months, with thrombocytopenia, hepatic failure, oral anticoagulation (but not antiplatelets) Saltissi et al.NS22--8517/193--5 h 3×/wkChronic HDbleeding disorders, anticoagulation therapy (warfarin, aspirin) Stefoni et al.63.7 ± 7NS39/154 h 3×/wkChronic HD for at least 12 monthsactive gastrointestinal bleeding, myeloproliferative disorders, malignant diseases, hereditary deficiency of coagulation factors, LAC phenomenon, antiphospholipid syndromeCross-over without randomization Al-Saran et al.46.83 ± 14.63NS17/63--4 h 3×/wkat least 6 months on HD prior to studybleeding disorders, anemia with hemoglobin levels less than 10 g/dL, recent trauma, surgery, infectious disease or hemorrhagic disorder (\< 1 month) in addition to those receiving oral or other forms of anticoagulant therapy (e.g. warfarin, aspirin), or drugs that could affect heparin activity (e.g. tetracyclines, digitalis, and antihistamines) Bambauer et al.60NS12/15NSChronic HDNS Bramham et al.61 ± 15NS65/453--4 h 3×/wkChonic HD on monitoring shiftRenal transplant, transferred to satellite unit, switched to PD, on warfarin Deuber et al. (part 1)53 ± 747--65NS4 h 3×/wkchronic HD for at least 18 monthsNSDeuber et al. (part 2)50 ± 1820--67NS4 h 3×/wkchronic HD for at least 18 monthsNS Kronenberg et al.44.7 ± 16.8NS13/113.5--5 h 3×/wkin pre-dialysisdiabetes, bleeding disorders, oral anticoagulants, lipid lowering drugs Lai et al.42.2 ± 5.224--6025/1510--16 h/wkChronic HDdiabetes, primary hyperlipidemia Leu et al.57.8 ± 9.8NS7/134 h 3×/wkChronic HD at least 6 monthspts with lipid lowering drugs except non-diabetic pts. under lovastatin for \>6 months, known hemorrhagic diathesis, low platelet count, liver insufficiency, hypersensitivity to heparin Schmitt et al.58.637--7213/94--5.8 hchronic HD, cholesterol \>200 mg/dLdiabetes, concomittant drug treatment (lipid lowering drugs, COX inhibitors) Yang et al. (part 1)44 ± 15NS7/33×/wkchronic HD, non diabeticNS Yang et al. (part 2)57 ± 6.4NS7/33×/wkchronic HD with diabetes type IINSParallel with randomization Elisaf et al.NS15--61NS4 h 3×/wkchronic HDdiabetes, hyperlipidemia (primary or secondary) Nurmohamed et al.NSNSNS4--6 h 2-3×/wkchronic HDNS Schrader et al.54.0 ± 15.2 (LMWH)\
51.6 ± 17.9 (UFH)NS21/14 (LMWH)\
19/16 (UFH)NSpre-HD requiring HD, not on heparin in prior 3 monthsbleeding disorders, needed antiplatelets or anticoagulants*NS* not specified, *HD* hemodialysis, *PD* peritoneal dialysis, *hrs* hours, *wk.* week, *DVT* deep venous thrombosis, *VTE* venous thromboembolism, *AVF* arteriovenous fistula

Quality assessment {#Sec11}
------------------

Based on the analysis with the Cochrane risk of bias tool for randomized studies (Fig. [2](#Fig2){ref-type="fig"}), we observed a high rate of potential performance bias mainly caused by a lack of blinding and only few measures to ensure similar care to the patients independently from heparin type. Blinding, or lack of it, could also affect outcome detection (detection bias). We judged that there was a high risk of bias when the outcome of interest was subjective. Bleeding events were categorized as being minor or major in eight out of nine studies, but most of the time no clear definition was provided except for one study. \[[@CR27]\] The lack of definition made the evaluation of bleeding events subjective. In randomized trials, concealment was not specified, leading to an imprecise risk of selection bias for these studies. Overall, attrition and reporting biases were adequately handled through the trials (Fig. [2](#Fig2){ref-type="fig"}). Similarly, non-randomized cross-over studies had a moderate to high risk of outcome measurement when bleeding events evaluation was based on subjective assessment due to lack of clear outcome definition. The Robins-I tool points also to a missing data problematic due to drop-outs. (Fig. [3](#Fig3){ref-type="fig"}) The weighted kappa was 0.72 for Cochrane risk of bias tool and 0.69 for Robins-I, indicating a substantial agreement between raters.Fig. 2Cochrane risk of bias tool diagram Fig. 3Risk of Bias in non-randomized studies (Robins-I) diagram

Synthesis of individual studies results {#Sec12}
---------------------------------------

Not all studies had a predefined definition of the outcome of interest. Bleeding outcome was specified in the method section in only half of the studies \[[@CR15], [@CR22], [@CR24], [@CR27], [@CR28]\]. All except one \[[@CR14]\] reported bleeding events as minor or major. Only Stefoni et al. provided a clear definition of major (melena, hematemesis and arterial epistaxis) and minor bleeding (venous epistaxis, subconjuctival hemorrhage or prolonged bleeding from the cannulation site after removal of the dialysis needle) \[[@CR27]\]. For Bramham et al., a bleeding event was defined as a prolonged compression time or any other bleeding episode reported during or between dialysis sessions by the patients, including epistaxis or conjunctival bleeding \[[@CR15]\]. Among all bleeding events, only two were categorized by the authors as major, and both occurred in the LMWH group. When combining both major and minor bleedings, 24 (6.6%) events were recorded for LMWH compared to 31 (8.5%) for UFH. Bleeding outcomes are presented in Table [3](#Tab3){ref-type="table"}.Table 3Bleeding events and relative risk with 95% CI for LMWH compared to UFHStudy, yearTotal bleeding events LMWH (n/N)Total bleeding events UFH (n/N)RR (95% CI)CommentsAl-Saran et al.3/230/237.00 (0.38--128.33)3 minor bleedings with LMWH, controlled with dose adjustmentBambauer et al.3/276/270.50 (0.14--1.80)No indication if minor or major bleeding eventsBramham et al.0/1104/1100.11 (0.01--2.04)4 minor bleeding episodes with UFHLord et al.3/328/320.38 (0.11--1.29)LMWH: 1 major and 2 minor bleedings; UFH: 8 minor bleedingsNurmohamed et al.3/350/357.00 (0.37--130.69)3 minor bleeding events with LMWHSaltissi et al.^a^12/366/362.00 (0.84--4.75)LMWH:1 major and 11 minor bleedings; UFH: 6 minor bleedingsStefoni et al.0/547/540.07 (0.00--1.14)7 minor bleeding events with UFHSchrader et al.^b^0/350/35excludedn/aYang et al. (part 1)^b^0/100/10excludedn/aSummary24/36231/3620.76 (0.26--2.22)^a^Details of bleeding events extracted from Lim et al.^b^Studies excluded due to "zero cells" in both LMWH and UFH groups

Cardiovascular events were reported in two studies; while Bambauer et al. \[[@CR14]\] recorded two events with LMWH and three for UFH, Schrader et al. \[[@CR26]\] observed two events with LMWH and one event with UFH. The majority of the studies showed a decrease in lipid levels using LMWH except for three which reported either an increase or no changes for cholesterol, \[[@CR19], [@CR26]\] LDL-cholesterol \[[@CR19], [@CR24]\] and triglycerides \[[@CR24], [@CR26]\]. The beneficial effect on lipids was less pronounced when using UFH where cholesterol, LDL-cholesterol and triglycerides increased or remained stable in five, \[[@CR17], [@CR21], [@CR24]--[@CR26]\] three \[[@CR21], [@CR24], [@CR25]\] and six \[[@CR17], [@CR21], [@CR25]--[@CR28]\] studies, respectively (Tables [4](#Tab4){ref-type="table"}-S1-S2).Table 4LDL-cholesterol weighted mean differenceStudyLMWHUFHmean change, SD (mg/dl)mean change, SD (mg/dl)WMD (95% CI) (mg/dl)Al-Saran et al.^a^−30.94 ± 39.52−20.11 ± 44.69−10.83 (−35.21, 13.55)Elisaf et al.−18 ± 36.86−2 ± 32.78−16.00 (−31.69, −0.31)Kronenberg et al.12.3 ± 36.68−16.5 ± 33.8428.80 (8.83, 48.77)Lai et al.^a^−2.70 ± 36.93−6.57 ± 45.823.87 (−14.37, 22.11)Leu et al.^a^−35.96 ± 35.0331.71 ± 36.80−67.67 (−89.94, −45.40)Saltissi et al.^a^0.39 ± 29.011.55 ± 30.55−1.16 (−14.92, 12.60)Schmitt et al.−27 ± 51.1021 ± 48.12−48.00 (−77.33, −18.67)Summary−14.88 (−36.27, 6.51)^a^Results were expressed in mmol/L, we converted them in mg/dl to be able to pool them

No study evaluated the incidence of osteoporotic fractures. Osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL) levels were measured in two studies. The OPG/RANKL system is involved in bone metabolism. No significant difference between LMWH and UFH (Additional file [2](#MOESM2){ref-type="media"}: Table S3) was found \[[@CR16], [@CR29]\]. Lai et al. \[[@CR20]\] measured the bone densitometry with dual energy X-ray and observed an increase of bone mass density (BMD) in ward's triangle by 0.75% after switching to LMWH. This increase did not reach statistical significance (*p* = 0.11). The mean BMD in the same region decreased by 2.38% after patients were back on UFH \[[@CR20]\]. They did not observe a similar trend for the other sites investigated.

Bramham et al. \[[@CR15]\] reported that they did not observe any case of thrombocytopenia among their patients during the study follow-up for both LMWH and UFH.

Meta-analysis results {#Sec13}
---------------------

Schrader et al. \[[@CR26]\] and Yang et al. \[[@CR28]\] were excluded from the analysis since they did not have any bleeding event in both LMWH and UFH groups. The overall RR for total bleeding (minor and major) with LMWH compared to UFH was 0.76 (95% CI: 0.26, 2.22) using a random effect model. The I^2^ statistic for heterogeneity was statistically significant (*p* = 0.018) (Fig. [4a](#Fig4){ref-type="fig"}). Compared to UFH, LMWH showed lower cholesterol level, with a pooled WMD of −28.70 mg/dl (95% CI: -51.43, −5.98) (Fig. [4c](#Fig4){ref-type="fig"}). A pooled WMD of −55.57 mg/dl (95% CI: -94.49, −16.66) was calculated for triglycerides showing lower levels in the LMWH group compared to UFH (Fig. [4d](#Fig4){ref-type="fig"}). A similar trend was observed with LDL-cholesterolbut the results were not statistically significant (pooled WMD: −14.88 mg/dl (95% CI: -36.27, 6.51)) (Fig. [4b](#Fig4){ref-type="fig"}). Results were pooled using random effect model as the heterogeneity test was statistically significant. Because of the small number of studies, visual interpretation of the funnel plots to assess possible publication bias was inconclusive (Additional file [2](#MOESM2){ref-type="media"}). The Egger test results indicated a potential publication bias (data not presented).Fig. 4Meta-analysis results for (**a**) total bleeding relative risk and confidence interval, (**b**) LDL-cholesterol, (**c**) Total cholesterol and (**d**) Triglycerides weighted mean difference and confidence interval for LMWH compared to UFH. Abbreviations: WMD, weighted mean difference, CI, confidence interval

Sensitivity analyses {#Sec14}
--------------------

Using different correlation factors to calculate the standard deviation of the mean changes for cholesterol, LDL-cholesterol and triglycerides rendered similar results. With a correlation factor of 0.3 the pooled WMD for cholesterol, triglycerides and LDL were, −27.38 mg/dl (95% CI: -50.78, −3.98), −53.76 mg/dl (95% CI: -94.98, −12.53) and −14.49 mg/dl (95% CI: -35.73, 6.75) respectively. A correlation factor of 0.8 resulted in pooled WMD for cholesterol, triglycerides and LDL of −32.25 mg/dl (95% CI: -55.08, −9.42), −60.78 mg/dl (95% CI: -97.74, −23.83) and −15.49 mg/dl (95% CI: -37.56, 6.57) respectively.

Discussion {#Sec15}
==========

This systematic review reports on safety of LMWH compared to UFH when used for anticoagulation of the extracorporeal circuit during hemodialysis. There was no statistical difference for risk of bleeding in the LMWH compared to the UFH group. We also showed lower levels of total cholesterol and triglycerides when exposed to LMWH compared to UFH. LDL-cholesterol levels tended to be lower using LMWH but the difference did not reach statistical significance. Because of the small numbers of studies, we were not able to estimate the differential risk of cardiovascular events, osteoporotic fractures and HIT.

A decade after the publication of the first meta-analysis published by Lim et al. \[[@CR6]\], we conducted a new systematic review to re-evaluate LMWH bleeding risk in hemodialysis compared to UFH by including all new relevant studies. Lim et al. found similar overall bleeding risk (RR = 0.96, 95% CI: 0.27, 3.43), a result that is consistent with our study. Our updated meta-analysis adds to this earlier study by narrowing the CI and reducing the upper limit from three to two, supporting that, at least, LMWH does not carry a higher risk of bleeding. Our results are also consistent with observed bleeding risk among patients without renal failure using LMWH for their primary indication \[[@CR32], [@CR33]\]. Renal-dependent clearance of LMWH remains a concern. A prospective observational cohort study evaluated the bioaccumulation of dalteparin when administered at the therapeutic dose twice a day. Patients with a glomerular filtration rate (GFR) inferior to 30 mL/min/1.73 m^2^ showed a significant bioaccumulation of dalteparin at the end of the study \[[@CR34]\]. On the other hand, two studies were conducted among critically ill patients with severe renal insufficiency, and did not observe bioaccumulation of dalteparin using a prophylactic dose of 5000 IU once a day \[[@CR35], [@CR36]\]. The later schedule is closer to the hemodialysis context.

No prior systematic review compared LMWH and UFH for cardiovascular events and lipid profile in hemodialysis. UFH is known to activate lipoprotein lipase and hepatic lipase and therefore to affect lipid profil \[[@CR7]\]. Unfortunately, data on cardiovascular events were limited. Although it was demonstrated in the SHARP study \[[@CR37]\] and a meta-analysis \[[@CR38]\] that, for patients with chronic kidney disease, lowering LDL-cholesterol by 38.61 mg/dl (1 mmol/L) induced a reduction of 17% of major atherosclerotic events, in dialysis-dependent patients there is only a weak association between LDL-cholesterol level and the risk of cardiovascular event \[[@CR39]\]. Indeed, low LDL-cholesterol level could be associated with a high risk of cardiovascular event in dialysis patients when there is coexistence of malnutrition and inflammation \[[@CR40], [@CR41]\]. While our results were in favor of LMWH, it remains uncertain whether the decrease would translate into lower cardiovascular events among ESRD patients.

Our meta-analysis is the first to compare LMWH and UFH for bone metabolism in hemodialysis. The exact mechanism involved in osteoporosis induced by UFH remains unclear. One hypothesis suggests a suppression of osteoblast formation and activation of osteoclasts promoting bone loss \[[@CR5]\]. Unfortunately, no study compared osteoporotic fractures. Different studies presented the OPG/RANKL system as an actor of bone remodeling \[[@CR42], [@CR43]\]. No difference was detected in the studies retrieved \[[@CR16], [@CR29]\]. While it is reported that LMWH cause less bone loss among pregnant women, these results were not replicated among hemodialysis patients \[[@CR7]\]. Uncertainty was raised in the Kidney Disease Improving Global Outcomes (KDIGO) clinical guidelines in 2009 about the reliability of BMD measured with dual energy X-ray \[[@CR44]\]. However a systematic review and meta-analysis conducted by Bucur et al. \[[@CR45]\] showed that BMD is lower in chronic kidney disease (CKD) patients with fracture compared to CKD patients without fracture, suggesting that BMD could still be clinically relevant to evaluate fracture risk in CKD.

Thrombocytopenia is a rare but severe adverse reaction to heparin. Although Bramham et al. \[[@CR15]\] did not observe any HIT; we cannot reach any conclusion regarding this outcome. The incidence of thrombocytopenia was reported between 1 and 3% with UFH, while it was less than 1% with LMWH \[[@CR46]\]. UFH binds to the platelet factor 4 (PF4). Antibodies then recognize this complex, which leads to an autoimmune reaction and thrombocytopenia \[[@CR47]\]. Because a long chain of saccharides is needed to bind to PF4, and that LMWH are composed of short chains, it is believed that LMWH is less likely to form such complexes \[[@CR48]\].

Our review has some limitations. Except for bleeding and cardiovascular events, we could not obtain data on every one of our primary outcomes. Our analyses were based on the secondary outcomes, and they might not be effective surrogates to infer on the main outcomes. The bleeding risk with LMWH may have been misestimated as some of the studies included an exploratory phase to determine the right LMWH dosage, which is partly based on occurrence of bleeding events, while UFH treatment arm did not go through such phase since patients were already stable under that regimen.

The potential publication bias detected must be taken into consideration when interpreting the results. Although the use of objective searching methods we could not eliminate this bias. Because of the lack of clear and consistent definition of major and minor bleeding in the retrieved studies, we opted to evaluate the risk of total bleeding. However, it would have been interesting to measure the risk of hemorrhage according to its severity, where major bleeding has a greater impact on the patient but also on the type of care needed \[[@CR49]\]. A standardized definition of major and minor bleeding needs to be used in future investigations; such definition is already provided by the subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis \[[@CR49]\].

The random effect model cannot compensate for the entire heterogeneity found between studies. High heterogeneity could be caused by multiple factors. The inclusion of different study designs in our review. We believe that the crossover and parallel-design should not be different for the measured outcomes in this context. Because of the small number of trials, it was not possible to analyze LMWH separately. LMWH have different pharmacokinetics and kidney failure does not alter similarly their elimination. For instance, enoxaparin might seem safe when there is clear evidence of its bioaccumulation \[[@CR50], [@CR51]\]. Finally, the trials used different doses and had variable follow-up time. The dosage, the use of low or high flux dialysis, types of membranes, hemodiafiltration and hemodialysis procedures, all these factors would contribute to the measured heterogeneity.

Conclusion {#Sec16}
==========

In conclusion, the available data does not allow to determine which heparin form is safer when used for anticoagulation of the extracorporeal circuit during hemodialysis. The risk of hemorrhage was not statistically significant when LMWH was compared to UFH, and lipid levels remained comparable or lower with LMWH. As for osteoporosis and thrombocytopenia, the data does not allow making a reliable comparison with UFH. The potential sources of bias discussed earlier and the quality level of the retrieved studies hinder the interpretation of observed results. LMWH have been used in hemodialysis for many years, but we are still in dire need of trials addressing the aforementioned limitations. Future studies need to use larger sample size during a sufficiently long follow-up and a clearer definition of the outcome measured to make their results usable and interpretable. Anticoagulation is mandatory for most patients undergoing hemodialysis treatments, and the choice of anticoagulation agent must be supported by stronger evidence.
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BMD

:   Bone mass density
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:   Confidence intervals

CKD

:   Chronic kidney disease

ECC

:   Extracorporeal circuit

ESRD

:   End-stage renal disease

HIT

:   Heparin-induced thrombocytopenia

KDIGO

:   Kidney Disease Improving Global Outcomes

LMWH

:   Low molecular weight heparins

MWD

:   Mean weighted difference

PF4

:   Platelet factor 4

RR

:   Relative risks

UFH

:   Unfractionated heparin

WMD

:   Weighted mean difference
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